Risk of diabetes in patients treated with HMG-CoA reductase inhibitors
- 1 April 2015
- journal article
- research article
- Published by Elsevier in Metabolism
- Vol. 64 (4) , 482-488
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Risk of incident diabetes among patients treated with statins: population based studyBMJ, 2013
- Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes MellitusThe American Journal of Cardiology, 2013
- Statins and risk of treated incident diabetes in a primary care populationBritish Journal of Clinical Pharmacology, 2012
- Management of Cardiovascular Risk: The Importance of Meeting Lipid TargetsThe American Journal of Cardiology, 2012
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsThe Lancet, 2010
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial???Lipid Lowering Arm (ASCOT-LLA)Drugs, 2004
- MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trialThe Lancet, 2003
- Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialThe Lancet, 2002
- Pravastatin and the Development of Diabetes MellitusCirculation, 2001